Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
about
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusDipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitusPlace of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statementIncretin based therapies: a novel treatment approach for non-alcoholic fatty liver diseaseAssessment of pancreatic β-cell function: review of methods and clinical applicationsSafety and efficacy of sitagliptin-metformin in fixed combination for the treatment of type 2 diabetes mellitusGemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes MellitusDipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participantsAddition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysisColesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapyDipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trialsRisk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trialsConsensus report: the current role of self-monitoring of blood glucose in non-insulin-treated type 2 diabetesEmerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetesCardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials.Effects of a sitagliptin safety alert on prescription behaviour for oral antihyperglycaemic drugs: a propensity score-matched cohort study of prescription receipt data in Japan.Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis.Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes.Dipeptidyl-peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrationsAddition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks.Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus.Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes.Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetesComparison of the efficacy of sitagliptin and glimepiride dose-up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination.Predictive factors of durability to sitagliptin: Slower reduction of glycated hemoglobin, older age and higher baseline glycated hemoglobin.Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agentsGliptins: a new class of oral antidiabetic agentsComparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparisonLiraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapyPro's and con's of the early use of insulin in the management of type 2 diabetes: a clinical evaluation.Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis.Sitagliptin in the treatment of type 2 diabetes: a meta-analysis.Emerging treatment options for type 2 diabetesFactors influencing the durability of the glucose-lowering effect of sitagliptin combined with a sulfonylurea.Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylureaGLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies.Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes.
P2860
Q24235718-7DF07161-902A-41F8-BE7D-DD9DC11E026BQ24240522-8EA9D3B8-6EA0-4686-BBA9-A7BED5AA3922Q24243196-1E14E4FC-486D-42FC-871E-061F36673F4DQ26783199-34D02EEE-AF41-4C0E-9CD1-E908643F68FEQ26827183-BE4A91CF-AD71-47F1-BD96-DFB8105B9BD6Q26829445-26945654-D55D-4713-B54D-2492F9087845Q27027877-90CAE63F-6705-456C-A292-B913711FEB98Q28066209-44768852-747F-4D3A-A053-FF6071A52549Q28238585-86052883-59F6-4132-A029-6D1C412B22BFQ28275281-A7A631C1-CF9D-4339-AB97-6E82FE3F0824Q28279020-5F59A6C4-1A08-49D1-B14F-A369B813C5B2Q28294225-C9D48C36-AB50-437D-AE94-BAE23169BBA3Q28544980-5A6F2163-7D4B-4ED1-8C4C-4EB651773C37Q28732681-69F415B5-BFFA-488B-A74F-667866EB3579Q28762629-17E142E6-A0B5-4E86-9970-90745564F763Q30240823-3CC58958-FF3A-4E44-B737-A4C13434D4FDQ30631209-67AA7143-7A49-44E3-BCCA-F1F0DB32750FQ30846870-E4D83F73-D888-4766-855A-3A9E39F93689Q33562235-0D28DC8C-8D49-4EA0-AE53-E68004C1E1C9Q33587800-E85C4187-BDDB-4AAF-B96C-9778F81DA612Q33603409-7722DBE8-0E42-435C-9E05-10FA0AFE1E2EQ33603545-6705544B-C8DC-4F6B-BAFB-41E975049273Q33603551-003D8E87-21BF-4751-AFD6-89C749AC9806Q33607755-05019DCF-FDC6-4EEF-9195-3CA61F97942FQ33608096-07475C76-EE93-42C4-9A85-5BCD312816CEQ33628631-D088B60F-5971-4768-B16F-C6D4DA0E0EECQ33731748-EB21F9BE-2A76-4F2A-8E41-9935E896A297Q33757148-6D63F249-68EE-4CBF-A50E-23E82E39F469Q33785197-5AA9282F-F580-4F36-8461-1CD0A5B3684DQ33854032-85FBB140-3663-43D3-B555-AF0168463C10Q33859245-02207861-698B-46FE-A384-C1911F1E99C2Q33980529-59A6AFF2-671E-48AD-BF2D-EE5A2B6BF80DQ34078449-73E5510C-5873-48E1-8DDA-1F63099E25D4Q34344570-CAFF13B6-238B-43E9-B29D-7783346E7253Q34381281-920F975E-FFF8-4B52-80A9-B13EC7ED8152Q34407909-5CE86502-0304-4443-966F-87DC3F6D73E3Q34543050-697D68A9-8592-475C-B787-792EA6F5A7E1Q34547492-08D314B8-1584-4E6D-948C-9DAF36848DD3Q34620430-04DF9A61-F52F-47BC-9013-9E5F2FAEC3A7Q34620693-1548EF8E-717F-467D-A73B-0D6ABEECD0D7
P2860
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Efficacy and safety of the dip ...... on glimepiride and metformin.
@en
Efficacy and safety of the dip ...... on glimepiride and metformin.
@nl
type
label
Efficacy and safety of the dip ...... on glimepiride and metformin.
@en
Efficacy and safety of the dip ...... on glimepiride and metformin.
@nl
prefLabel
Efficacy and safety of the dip ...... on glimepiride and metformin.
@en
Efficacy and safety of the dip ...... on glimepiride and metformin.
@nl
P2093
P2860
P921
P1476
Efficacy and safety of the dip ...... on glimepiride and metformin.
@en
P2093
K Hermansen
Sitagliptin Study 035 Group
P2860
P304
P356
10.1111/J.1463-1326.2007.00744.X
P577
2007-06-26T00:00:00Z